Compare with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

KRSNAA DIAGNOSTICS vs VIJAYA DIAGNOSTIC - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    KRSNAA DIAGNOSTICS VIJAYA DIAGNOSTIC KRSNAA DIAGNOSTICS/
VIJAYA DIAGNOSTIC
 
P/E (TTM) x - - - View Chart
P/BV x 9.6 16.5 58.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 KRSNAA DIAGNOSTICS   VIJAYA DIAGNOSTIC
EQUITY SHARE DATA
    KRSNAA DIAGNOSTICS
Mar-21
VIJAYA DIAGNOSTIC
Mar-21
KRSNAA DIAGNOSTICS/
VIJAYA DIAGNOSTIC
5-Yr Chart
Click to enlarge
High RsNANA-   
Low RsNANA-   
Sales per share (Unadj.) Rs998.883.1 1,201.5%  
Earnings per share (Unadj.) Rs284.518.7 1,518.5%  
Cash flow per share (Unadj.) Rs342.129.9 1,145.4%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %NMNM- 
Book value per share (Unadj.) Rs355.579.2 448.7%  
Shares outstanding (eoy) m6.5045.32 14.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x00-   
Avg P/E ratio x00-  
P/CF ratio (eoy) x00-  
Price / Book Value ratio x00-  
Dividend payout %00-   
Avg Mkt Cap Rs m00-   
No. of employees `000NANA-   
Total wages/salary Rs m296574 51.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m6,4923,767 172.3%  
Other income Rs m122118 103.3%   
Total revenues Rs m6,6153,886 170.2%   
Gross profit Rs m3,4661,660 208.8%  
Depreciation Rs m374505 74.2%   
Interest Rs m259152 170.1%   
Profit before tax Rs m2,9551,121 263.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,105272 406.1%   
Profit after tax Rs m1,849849 217.8%  
Gross profit margin %53.444.1 121.2%  
Effective tax rate %37.424.3 154.1%   
Net profit margin %28.522.5 126.4%  
BALANCE SHEET DATA
Current assets Rs m2,4812,388 103.9%   
Current liabilities Rs m1,838440 417.9%   
Net working cap to sales %9.951.7 19.2%  
Current ratio x1.45.4 24.9%  
Inventory Days Days2545 55.0%  
Debtors Days Days416 656.3%  
Net fixed assets Rs m3,5642,961 120.4%   
Share capital Rs m2,48945 5,491.7%   
"Free" reserves Rs m-1783,545 -5.0%   
Net worth Rs m2,3103,590 64.4%   
Long term debt Rs m1,68033 5,128.4%   
Total assets Rs m6,0455,348 113.0%  
Interest coverage x12.48.4 148.3%   
Debt to equity ratio x0.70 7,968.6%  
Sales to assets ratio x1.10.7 152.5%   
Return on assets %34.918.7 186.3%  
Return on equity %80.023.7 338.4%  
Return on capital %80.535.2 229.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m00-   
Fx outflow Rs m00-   
Net fx Rs m00-   
CASH FLOW
From Operations Rs m1,0261,296 79.1%  
From Investments Rs m-611-1,298 47.1%  
From Financial Activity Rs m308-488 -63.2%  
Net Cashflow Rs m723-489 -147.8%  

Share Holding

Indian Promoters % 27.4 54.8 50.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 36.2 39.3 92.1%  
FIIs % 6.0 13.7 43.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 72.6 45.2 160.6%  
Shareholders   75,554 120,570 62.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare KRSNAA DIAGNOSTICS With:   DR.AGAR.EYE  DR LALCHANDANI LABS  TRANSGENE BI  GIAN LIFE CARE  DHANVANTRI JEEV  



Today's Market

Sensex, Nifty Trade Flat; Telecom & Healthcare Stocks Under Pressure(10:30 am)

Asian stock markets are trading on a mixed note today as traders evaluated risks from the omicron virus strain.

Related Views on News

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

5 Indian Companies Embracing Blockchain Technology(Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

KRSNAA DIAGNOSTICS SHARE PRICE


Dec 3, 2021 03:35 PM

TRACK KRSNAA DIAGNOSTICS

  • Track your investment in KRSNAA DIAGNOSTICS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON KRSNAA DIAGNOSTICS

KRSNAA DIAGNOSTICS 8-QTR ANALYSIS

COMPARE KRSNAA DIAGNOSTICS WITH

MARKET STATS